Wegovy lifts Novo outlook

Novo Nordisk raised its full-year outlook, supported by sales of Wegovy, forecasting that sales and profits could grow by as much as 2% at constant exchange rates. It also narrowed its worst-case forecast to a 2% decline, from 6%. Shares rose as much as 6.6% to a six-month high after adjusted operating profit jumped 34% in the latest quarter to 31.7 billion Danish kroner ($4.8 billion), beating analysts’ expectations.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article